Printer Friendly

J. MICHAEL BISHOP, M.D., JOINS SYNTEX'S BOARD COMMITTEE ON SCIENCE

 PALO ALTO, Calif., Jan. 29, /PR Newswire/ -- The board of directors of Syntex Corp. (NYSE: SYN) has elected J. Michael Bishop, M.D., 57, of the University of California, San Francisco, to the Syntex Board Committee on Science.
 The committee, chaired by Syntex founding chairman, Dr. George Rosenkranz, was created in recognition of the fundamental role scientific research plays at Syntex. It serves in an advisory capacity to Syntex Research concerning research strategy, research projects in progress, and project proposals for future implementation.
 Bishop brings to the committee expertise in the areas of molecular and cell biology and biochemistry. He is a world-renowned scientist who was honored with the Albert Lasker Award in 1982 and the Nobel Prize in Physiology and Medicine in 1989. These honors were awarded in recognition of his work with Harold Varmus, M.D., professor of microbiology, biochemistry and biophysics at UCSF on the role of genes in causing cancer.
 Bishop is currently a professor of microbiology and immunology, biochemistry and biophysics at UCSF. In addition, he is director of the George W. Hooper Research Foundation at UCSF, and a member of the National Academy of Sciences.
 "It is Dr. Bishop's superb knowledge of science along with his well-rounded education and wide-ranging interests that we believe make him ideally suited to serve on the Syntex Board Committee on Science," Rosenkranz said.
 Additional Science Committee members from academia include Kenneth Melmon, M.D., Department of Medicine, Stanford University; Dr. Elias Corey, Sheldon Emery Professor of Chemistry, Harvard University; and Julius R. Krevans, M.D., Chancellor, UCSF.
 Syntex is a multinational healthcare company that discovers, develops, manufactures and markets prescription medicines that treat serious human diseases. Syntex also develops, manufactures and markets animal pharmaceutical products and medical diagnostic systems.
 -0- 1/29/93
 /CONTACT: Linda Thomas of Syntex, 415-852-1321/
 (SYN)


CO: Syntex Corp. ST: California IN: MTC SU: PER

TM -- SJ004 -- 0536 01/28/93 18:27 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 28, 1993
Words:320
Previous Article:PIONEER BANK'S SHAREHOLDERS APPROVE MERGER WITH WASHINGTON MUTUAL
Next Article:OREGON STEEL MILLS INC. ANNOUNCES QUARTERLY DIVIDEND
Topics:


Related Articles
SYNTEX APPOINTS NEW RESEARCH LEADERSHIP
SYNCOR APPOINTS HENRY N. WAGNER, JR., M.D. TO BOARD OF DIRECTORS
SYNTEX APPOINTS NEW PRESIDENT OF U.S. PHARMACEUTICALS MARKETING SUBSIDIARY
SYNTEX ELECTS NEW DIRECTOR; FINANCIAL EXECUTIVE JOINS SYNTEX CORP. BOARD
SYNTEX APPOINTS TSCHUDIN TO HEAD SYNTEX PHARMACEUTICALS-EUROPE
SCICLONE PROMOTES SHAWN SINGH TO VICE PRESIDENT, BUSINESS DEVELOPMENT AND HIRES MEDICAL DIRECTOR
CUBIST PHARMACEUTICALS, INC. ANNOUNCES APPOINTMENT OF ARTHUR F. KLUGE, PH.D. AS VICE PRESIDENT OF CHEMISTRY
SUNPHARM ESTABLISHES PHARMACEUTICAL ADVISORY BOARD
CELL THERAPEUTICS INC. NAMES CHIEF SCIENTIFIC OFFICER AND V.P. MARKETING AND BUSINESS DEVELOPMENT
David Smith Appointed Anergen CFO

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters